Gain access to palbociclib (Ibrance) resistant PDX models
CDK4/6 inhibitor drugs have yielded efficacious results in ER-positive, HER2-negative breast cancer patients and are being used as standard of scare (SOCs) drugs in combination with other SOCs such as fulvestrant. However, some patients are displaying resistance to new CDK4/6 inhibitor drugs such as ribociclib, abemaciclib, and palbociclib.
Envigo is offering early access to palbociclib (Ibrance) patient resistant PDX models through its licensed WHIM (Washington University Human in Mouse) collection from Washington University in St. Louis.
What you can expect working with us
Our in vivo tumor models and drug efficacy specialists can:
- Work with you to build an ideal experimental design offering extremely flexible design parameters for your custom drug efficacy study
- Provide all characterization data available to date on these PDX models to guide you in your model selection
- Generate key data points and provide clear and comprehensive efficacy data analysis
- Determine any downstream assays or material needed such as tumor chunks, tumor microarrays, FFPE blocks, and much more.
Want to know more?
If you'd like to discover more on the early access, fill out the form to the right to connect with an expert who will work with you to understand your research needs and how we can deliver the results you need today.
